Clearance of von Willebrand factor

被引:41
作者
Denis, Cecile V. [1 ,2 ]
Christophe, Olivier D. [1 ,2 ]
Oortwijn, Beatrijs D. [3 ]
Lenting, Peter J. [3 ,4 ]
机构
[1] INSERM, U770, F-94276 Le Kremlin Bicetre, France
[2] Univ Paris Sud, F-94275 Le Kremlin Bicetre, France
[3] Univ Med Ctr Utrecht, Lab Thrombosis & Haemostasis, Dept Clin Chem & Haematol, Utrecht, Netherlands
[4] Crucell Holland BV, Dept Prot Discovery, Leiden, Netherlands
关键词
von Willebrand factor; factorVIII; animal models; von Willebrand disease;
D O I
10.1160/TH07-10-0629
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The life cycle of von Willebrand factor (VWF) comprises a number of distinct steps, ranging from the controlled expression of the VWF gene in endothelial cells and megakaryocytes to the removal of VWF from the circulation. The various aspects of VWF clearance have been the objects of intense research in the last few years, stimulated by observations that VWF clearance is a relatively common component of the pathogenesis of type I von Willebrand disease (VWD). Moreover, improving the survival of VWF is now considered as a viable therapeutic strategy to prolong the half-life of factor VIII in order to optimise treatment of haemophilia A. The present review aims to provide an overview of recent findings with regard to the molecular basis of VWF clearance. A number of parameters have been identified that influence VWF clearance, including its glycosylation profile and a number of VWF missense mutations. In addition, in-vivo studies have been used to identify cells that contribute to the catabolism of VWF, providing a starting point for the identification of receptors that mediate the cellular uptake of VWF. Finally, we discuss recent data describing chemically modification of VWF as an approach to prolong the half-life of the VWF/FVIII complex.
引用
收藏
页码:271 / 278
页数:8
相关论文
共 85 条
[1]   Efficiency of von Willebrand factor-mediated targeting of interleukin-8 into Weibel-Palade bodies [J].
Bierings, R. ;
Van Den Biggelaar, M. ;
Kragt, A. ;
Mertens, K. ;
Voorberg, J. ;
Van Mourik, J. A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2512-2519
[2]   Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans [J].
Borchiellini, A ;
Fijnvandraat, K ;
tenCate, JW ;
Pajkrt, D ;
vanDeventer, SJH ;
Pasterkamp, G ;
MeijerHuizinga, F ;
ZwartHuinink, L ;
Voorberg, J ;
vanMourik, JA .
BLOOD, 1996, 88 (08) :2951-2958
[3]  
Bowen DJ, 2003, THROMB HAEMOSTASIS, V90, P961
[4]   Increased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process? [J].
Brown, SA ;
Eldridge, A ;
Collins, PW ;
Bowen, DJ .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (08) :1714-1717
[5]   O-LINKED CARBOHYDRATE OF RECOMBINANT VONWILLEBRAND-FACTOR INFLUENCES RISTOCETIN-INDUCED BINDING TO PLATELET GLYCOPROTEIN-1B [J].
CAREW, JA ;
QUINN, SM ;
STODDART, JH ;
LYNCH, DC .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) :2258-2267
[6]   Reduced von Willebrand factor survival in type Vicenza von Willebrand disease [J].
Casonato, A ;
Pontara, E ;
Sartorello, F ;
Cattini, MG ;
Sartori, MT ;
Padrini, R ;
Girolami, A .
BLOOD, 2002, 99 (01) :180-184
[7]   A mouse model of severe von Willebrand disease:: Defects in hemostasis and thrombosis [J].
Denis, C ;
Methia, N ;
Frenette, PS ;
Rayburn, H ;
Ullman-Culleré, M ;
Hynes, RO ;
Wagner, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9524-9529
[8]   HETEROGENEITY OF PLASMA VONWILLEBRAND-FACTOR MULTIMERS RESULTING FROM PROTEOLYSIS OF THE CONSTITUENT SUBUNIT [J].
DENT, JA ;
GALBUSERA, M ;
RUGGERI, ZM .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (03) :774-782
[9]   Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands [J].
Ellies, LG ;
Ditto, D ;
Levy, GG ;
Wahrenbrock, M ;
Ginsburg, D ;
Varki, A ;
Le, DT ;
Marth, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :10042-10047
[10]  
Esch Jan Schulte am II, 2005, British Journal of Haematology, V128, P82, DOI 10.1111/j.1365-2141.2004.05253.x